At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Netarsudil Ophthalmic +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Dosing Regimens of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
In Brief
A Phase 2 clinical trial evaluating Netarsudil Ophthalmic for Corneal Edema. Completed, enrolled 40 participants across 12 sites.
Detailed Summary
Two different dosing regimens (QD and BID) of netarsudil will be studied to evaluate their efficacy in reducing or resolving corneal edema in subjects with FCD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorneal Edema
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2020
Primary CompletionAug 2021
TodayJul 2026
First PostedAug 4, 2020
Enrollment StartSep 17, 2020
Primary CompletionAug 11, 2021
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.9 years ago
Interventions
Netarsudil Ophthalmicdrug
Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
Netarsudil Ophthalmicdrug
Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution